Bessemer Group Inc Arcutis Biotherapeutics, Inc. Transaction History
Bessemer Group Inc
- $60.7 Billion
- Q3 2024
A detailed history of Bessemer Group Inc transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Bessemer Group Inc holds 110 shares of ARQT stock, worth $1,456. This represents 0.0% of its overall portfolio holdings.
Number of Shares
110
Previous 360
69.44%
Holding current value
$1,456
Previous $3,000
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ARQT
# of Institutions
196Shares Held
130MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC12.3MShares$163 Million0.11% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$145 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$142 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$116 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$114 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $797M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...